IMMUCELL CORP /DE/ 8-K

What Happened

• Immucell Corp (ICCC) filed an 8-K reporting that director Steven A. Rosgen tendered his resignation on March 12, 2026 and will retire from the Board effective April 1, 2026.
• The Board elected Kathy V. Turner on March 12, 2026 to fill the vacancy, with her appointment—and committee assignments—effective April 1, 2026.

Key Details

• Resignation notice: Mr. Rosgen had previously indicated (in an 8-K filed Feb 9, 2026) he preferred not to run for re-election; formal resignation tendered March 12, 2026, effective April 1, 2026.
• New director: Kathy V. Turner has 30+ years of commercial leadership in global healthcare and animal health.
• Recent roles: Turner served on Elanco’s board (Apr 2024–May 2025), held senior leadership at IDEXX Laboratories (2014–2023) including CMO and SVP International Operations, and spent ~30 years at Abbott Laboratories.
• Committee roles: Turner will join the Audit Committee and serve as Chair of the Compensation and Stock Option Committee, effective April 1, 2026.
• No related-party transactions: The company stated it is not aware of any transaction involving Ms. Turner requiring Item 404(a) disclosure.

Why It Matters

• This is a governance change that maintains board continuity while adding a director with deep experience in animal health and global commercial operations—areas relevant to Immucell’s business.
• Turner's committee roles (Audit; Compensation/Stock Option) mean she will have direct influence on financial oversight and executive pay matters.
• The filing discloses no compensation or related-party arrangements tied to the appointment, and no other financial impacts were reported.